Long-Term Study of JNT-517 for Phenylketonuria (PKU)
This study is looking at the long-term safety of a medicine called JNT-517 for people with Phenylketonuria (PKU). PKU is a genetic condition where the body can't break down a substance called phenylalanine. You might be able to join if you are 4 years old or older and have PKU. This study is for people who have already been in a JNT-517 study, as well as those who haven't. All participants will receive JNT-517 by mouth twice a day, with the dose adjusted for your age and weight. The main goal is to see how many people experience side effects from JNT-517. The study plans to enroll 240 participants, but its current status is unclear.
- Study design
- This is a Phase 3, open-label study, meaning everyone knows they are receiving JNT-517. It aims to enroll 240 participants.
- What's involved
- You would take JNT-517 by mouth twice daily. The specific number of visits or procedures is not detailed in this record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored from the start of the study until two weeks after your last dose of JNT-517.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Long-Term Study of JNT-517 in Participants With Phenylketonuria
At a glance
Conditions
Where it's being run
12 sites across 8 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants with Treatment-emergent Adverse Events (TEAEs)Screening to +2 weeks from last dose
Reported based on results of 12-lead electrocardiograms (ECGs), vital signs, clinical laboratory tests, and other medical assessments.